Can Women Take Finasteride? What the Research Says

Hair loss in women is more common than most people realize — and more emotionally devastating than most people outside the experience can appreciate. Female pattern hair loss (FPHL), also called androgenetic alopecia, affects an estimated 40% of women by age 50. Yet the treatment options approved specifically for women remain frustratingly limited compared to what's available for men. That gap has led many women and their providers to look carefully at finasteride — a medication FDA-approved only for men — and ask whether it might work for women too.

The answer, based on accumulating research, is: sometimes yes, with important caveats. Here's what the science actually shows, and how to think about whether you might be a candidate.

What Is Finasteride?

Finasteride is a 5-alpha reductase inhibitor — a drug that blocks the enzyme (5-alpha reductase type II) responsible for converting testosterone into dihydrotestosterone (DHT). DHT is the androgen primarily responsible for miniaturizing hair follicles in genetically susceptible individuals, eventually causing them to stop producing visible hair.

By reducing DHT levels, finasteride slows or stops follicle miniaturization and, in many cases, allows follicles that were miniaturizing to partially recover. It's FDA-approved for men at 1 mg/day for male pattern hair loss (Propecia) and at 5 mg/day for benign prostatic hyperplasia (Proscar). It is not FDA-approved for women — but "off-label" use of approved medications by licensed providers is legal and common in medicine when evidence supports it.

Why DHT Matters in Female Hair Loss

Female pattern hair loss is androgenetically driven — though the relationship is more complex than in men. Not all women with FPHL have elevated androgens. However, DHT's activity at the follicle level appears to be a common driver even when circulating androgen levels are within the normal range. Some women have increased sensitivity of their follicle receptors to DHT even at normal circulating levels.

Women who are more likely to have an androgen component to their hair loss include those with:

• Polycystic ovary syndrome (PCOS)
• Elevated DHEA-S, free testosterone, or total testosterone on labs
• Signs of hyperandrogenism: acne, facial hair growth, irregular periods
• A family history of androgenetic alopecia on either parent's side
• Hair loss pattern consistent with FPHL (central thinning, maintained frontal hairline — often called a "Christmas tree pattern")

What Does the Research Show?

Postmenopausal Women

The strongest evidence for finasteride in women comes from postmenopausal populations. A 2020 review of multiple studies found that finasteride at doses of 1 mg to 5 mg per day produced hair density improvements in postmenopausal women with FPHL. One frequently cited study showed that 37% of postmenopausal women on finasteride 1 mg/day experienced hair regrowth, and a larger percentage experienced stabilization (no further loss) after 12 months.

Postmenopausal women are the preferred population partly because the absolute lack of estrogen and progesterone, combined with relatively higher androgen activity, makes their hair loss more clearly androgen-driven — and partly because pregnancy risk is absent (see safety section below).

Premenopausal Women with Hyperandrogenism

Studies in premenopausal women with confirmed hyperandrogenism (elevated androgens) and FPHL have also shown benefit from finasteride. A study comparing finasteride to spironolactone (another anti-androgen) in women with elevated androgens found both medications produced significant hair density improvements, with finasteride showing slightly stronger DHT suppression.

Premenopausal Women Without Confirmed Hyperandrogenism

Evidence is more mixed in this population. Some studies show benefit even in women with normal androgen levels, suggesting that local 5-alpha reductase activity in the scalp matters more than circulating androgen levels. Other studies show less consistent results. This is an area where individual provider assessment — including consideration of the pattern of hair loss, treatment history, and response to other interventions — guides decision-making.

Safety Considerations: The Critical Warning

The most important safety issue with finasteride in women of childbearing age is teratogenicity — the potential to cause birth defects. Specifically, finasteride can interfere with the normal development of male genitalia in a male fetus during the first trimester. Even touching crushed or broken finasteride tablets is warned against for pregnant women in the prescribing information for the men's medication.

For this reason:

• Finasteride is generally considered only for postmenopausal women, or premenopausal women using reliable contraception who have been thoroughly counseled about the risks
• Any woman considering finasteride must have a clear plan to immediately discontinue the medication if pregnancy is suspected or planned
• Women should not donate blood while taking finasteride (to prevent the drug from reaching pregnant recipients)

This is not a barrier to using finasteride appropriately — it is a clear parameter that defines who is a safe candidate. A licensed provider who specializes in hair loss can help you determine whether you meet the criteria.

Other Side Effects in Women

Beyond teratogenicity, finasteride is generally well-tolerated in women in clinical studies. Reported side effects are typically mild and may include:

• Headache
• Decreased libido (though this appears to be less common in women than men)
• Menstrual irregularities (in some premenopausal women)
• Breast tenderness

The "post-finasteride syndrome" that some men report — persistent sexual and neurological side effects after stopping the medication — has not been clearly documented in women in the medical literature, though data on this specifically in female populations is limited.

Alternatives and Complementary Treatments

Finasteride is one option in a broader toolkit for female hair loss. Other evidence-based treatments include:

• Minoxidil (topical or oral): The only FDA-approved treatment for female pattern hair loss. Works by prolonging the growth phase of hair follicles. Commonly used as a first-line treatment and can be combined with finasteride when appropriate.
• Spironolactone: An anti-androgen commonly used off-label for FPHL in women, particularly those with PCOS or hyperandrogenism. It works differently from finasteride but addresses a similar pathway.
• Low-level laser therapy (LLLT): FDA-cleared devices that may stimulate follicle activity through photobiomodulation. Can be used alongside other treatments.
• Platelet-rich plasma (PRP): Injections of concentrated growth factors from your own blood into the scalp. Evidence is accumulating for FPHL and other types of alopecia.
• Nutritional optimization: Addressing deficiencies in ferritin (iron), zinc, vitamin D, and protein can significantly affect hair growth when deficiencies are present.
• Hormonal optimization: For women in perimenopause or menopause, addressing estrogen and progesterone decline may help, as estrogen supports hair growth. Our article on thyroid and metabolism also covers how thyroid dysfunction — a common and underdiagnosed cause of hair loss in women — should be evaluated.

Getting Evaluated for Female Hair Loss

Before any treatment for hair loss in women, a thorough evaluation is essential. Hair loss in women can result from many causes beyond androgenetics — including thyroid disease, iron deficiency, nutritional deficiencies, autoimmune alopecia (alopecia areata), traction alopecia, telogen effluvium (stress-related shedding), and scarring alopecias. Treatment of androgenetic alopecia in the presence of an unrecognized other cause will be ineffective.

A comprehensive hair loss evaluation typically includes:

• Dermatoscopy to assess follicle health and pattern
• Complete blood count
• Ferritin, vitamin D, zinc, and folate levels
• Thyroid panel (TSH, free T4, free T3, and antibodies)
• Androgens: free and total testosterone, DHEA-S, DHT
• Hormonal status: estradiol, FSH, LH
• Prolactin

At Truventa Medical, our hair loss treatment program takes a comprehensive diagnostic approach before recommending any treatment — because the right treatment depends entirely on an accurate diagnosis.

The Bottom Line

Finasteride can be an effective treatment for female pattern hair loss — particularly in postmenopausal women and premenopausal women with confirmed hyperandrogenism who are not pregnant and using reliable contraception. The research is not yet at the level of the men's data, but it is growing and generally positive in the right populations. The key to success is appropriate patient selection, thorough diagnostic workup, and careful provider-guided monitoring.

If you've been dealing with hair thinning and feel like you've run out of options, finasteride may be worth discussing with a provider who specializes in women's hair health. There is more available — you just need the right evaluation to find it.